阿尔法放射治疗法研发商Alpha Tau Medical获得战略融资-动脉网

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

CISION 等信源发布 2025-04-28 20:59



可切换为仅中文







Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology

Oramed利用其战略资本市场专业知识来支持Alpha Tau的突破性癌症治疗技术。

Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts

加速多种晚期癌症疗法，包括：美国四项适应症的临床试验、生产规模扩大以及商业化努力。

Partnership unites two innovative therapeutic delivery pioneers – Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology

伙伴关系联合了两位创新的治疗递送先驱——Oramed的口服药物递送平台与Alpha Tau的精准放射递送技术。

NEW YORK

纽约

，

April 28, 2025

2025年4月28日

/PRNewswire/ -- Oramed Pharmaceuticals Inc. ('Oramed' or the 'Company'), (Nasdaq:

/PRNewswire/ -- Oramed Pharmaceuticals Inc.（“Oramed”或“公司”），（纳斯达克：

ORMP

) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, announced today that it has successfully closed a strategic investment in Alpha Tau Medical Ltd. (Nasdaq:

）（TASE：ORMP），注射药物口服递送解决方案领域的平台技术先驱，今天宣布已成功完成对Alpha Tau Medical Ltd.（纳斯达克：

DRTS

动态实时传输系统

), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT

)，创新的阿尔法辐射癌症治疗Alpha DaRT的开发者

. Through a registered direct offering (the 'offering'), an affiliate of Oramed purchased approximately 14.1 million Alpha Tau's ordinary shares, at a purchase price of

通过注册直接发行（“发行”），Oramed的关联公司以每股购买价购买了大约1410万股Alpha Tau的普通股，

$2.612

2.612美元

per share.

每股。

As part of this collaboration, the parties have entered into a comprehensive three-year service agreement whereby Oramed will provide Alpha Tau with investor and shareholder outreach, business strategic guidance, and capital markets expertise. This strategic investment aligns with Oramed's growth strategy to expand its footprint in innovative therapeutic delivery technologies, enabling Oramed to contribute to Alpha Tau's strategic direction while supporting its market presence and accelerating its path to commercialization.

作为此次合作的一部分，双方签订了一份为期三年的全面服务协议，根据协议，Oramed将为Alpha Tau提供投资者和股东拓展、业务战略指导以及资本市场专业知识。这项战略性投资与Oramed的成长战略相契合，旨在扩大其在创新治疗递送技术领域的影响力，使Oramed能够在支持Alpha Tau市场地位及加速其商业化进程的同时，为其战略方向做出贡献。

Additionally, Oramed will take an active governance role with the appointment of two directors to Alpha Tau's Board of Directors..

此外，Oramed 将通过任命两名董事进入 Alpha Tau 的董事会，发挥积极的治理作用。

Oramed CEO

Oramed首席执行官

Nadav Kidron

纳达夫·基德隆

commented, 'This strategic alliance with Alpha Tau represents an exceptional opportunity for Oramed to apply our capital markets and business development expertise in supporting what we believe is a truly groundbreaking medical technology. Both companies share a fundamental vision of revolutionizing therapeutic delivery – Oramed through oral administration of injectable drugs and Alpha Tau through precise delivery of radiation therapy to tumor sites.

评论道：“与Alpha Tau的这一战略联盟代表了Oramed一个绝佳的机会，可以运用我们在资本市场和业务发展方面的专业知识，来支持我们认为是一项真正具有突破性的医疗技术。两家公司都有着革命性治疗交付的共同愿景——Oramed通过口服注射药物，而Alpha Tau通过将放射治疗精准递送至肿瘤部位。”

We hold unwavering confidence in the exceptional potential of the Alpha DaRT technology platform and the strategic vision of Alpha Tau's leadership team. We anticipate significant advancements and milestone achievements as they execute their clinical and commercial roadmap.'.

我们对Alpha DaRT技术平台的卓越潜力和Alpha Tau领导团队的战略眼光充满坚定信心。我们期待他们在执行临床和商业路线图的过程中取得重大进展和里程碑式的成就。

Alpha Tau CEO

阿尔法陶首席执行官

Uzi Sofer

乌齐·索弗

added, 'We are delighted to welcome Oramed as a strategic partner and to leverage their extensive expertise in navigating diverse capital markets channels. There's a natural alignment between our companies' missions to transform how therapies are delivered to patients. This investment comes at the perfect time for Alpha Tau given the rapid expansion of our business activities, including four parallel trial approvals in the U.S., expansion into trials in multiple internal organs, and continued expansion of our manufacturing capacity and pre-commercial preparations.

补充道：“我们非常高兴欢迎Oramed成为我们的战略合作伙伴，并利用他们在驾驭不同资本市场渠道方面的广泛专业知识。我们公司的使命是改变疗法向患者交付的方式，这之间有着天然的契合。鉴于Alpha Tau业务活动的快速扩展，包括在美国获得四项平行试验批准、扩展至多个内部器官的试验以及持续扩大我们的生产能力和上市前准备，这项投资来得正是时候。

We look forward to a long and fruitful relationship with Oramed.'.

我们期待与Oramed建立长期且富有成效的合作关系。

About Oramed Pharmaceuticals

关于Oramed制药公司

Oramed Pharmaceuticals (Nasdaq:

奥拉梅德制药（纳斯达克：

ORMP

) (TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. The Company's novel Protein Oral Delivery (POD

）（特拉维夫证券交易所代码：ORMP）是注射药物口服递送解决方案领域的平台技术先驱。该公司创新的蛋白质口服递送（POD

™

) technology is designed to protect drug integrity and increase absorption. Oramed has offices in

）技术旨在保护药物完整性并提高吸收率。Oramed在

the United States

美国

and

和

Israel

以色列

。

About Alpha Tau Medical Ltd.

关于阿尔法陶医疗有限公司

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT

成立于 2016 年的 Alpha Tau 是一家以色列肿瘤治疗公司，专注于 Alpha DaRT 的研究、开发和潜在商业化。

for the treatment of solid tumors. The technology was initially developed by Prof.

用于治疗实体瘤。该技术最初由Prof.开发。

Itzhak Kelson

伊扎克·凯尔森

and Prof.

和教授。

Yona Keisari

约纳·凯萨里

from

从

Tel Aviv University

特拉维夫大学

。

Forward-looking statements

前瞻性声明

: This press release contains forward-looking statements, which may generally be identified by the use of the words 'anticipates,' 'expects,' 'intends,' 'plans,' 'should,' 'could,' 'would,' 'may,' 'will,' 'believes,' 'estimates,' 'potential,' 'target,' or 'continue' and variations or similar expressions and include statements on the collaboration between Alpha Tau and the Company.

本新闻稿包含前瞻性陈述，这些陈述通常可以通过使用“预期”、“预计”、“打算”、“计划”、“应该”、“可能”、“会”、“可以”、“将”、“相信”、“估计”、“潜在”、“目标”或“继续”等词语及其变体或类似表达来识别，并包括关于Alpha Tau与公司之间合作的陈述。

These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties in satisfaction of closing conditions for the contemplated transactions, risks and uncertainties discussed in the Company's most recent annual and quarterly reports and detailed from time to time in the Company's other filings with the Securities and Exchange Commission, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements.

这些声明基于管理层当前的预期和信念，并受某些风险和不确定性的约束，这些风险和不确定性可能导致实际结果与前瞻性声明中描述的结果存在重大差异。这些风险和不确定性包括但不限于与拟议交易相关的交割条件满足方面的不确定性、公司在最近的年度和季度报告中讨论的风险和不确定性，以及公司不时在向证券交易委员会提交的其他文件中详细说明的内容，所有这些因素均可能导致 Oramed 的实际结果或表现与前瞻性声明中考虑的内容存在重大差异。

These forward-looking statements speak only as of the date hereof. Oramed undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect actual outcomes, unless required by law..

这些前瞻性陈述仅截至本日期有效。除非法律要求，Oramed没有义务更新任何这些前瞻性陈述以反映本日期之后的事件或情况，或反映实际结果。

Logo:

标志：

https://mma.prnewswire.com/media/1724339/3464831/Oramed_Logo.jpg

Company Contact:

公司联系人：

+1-844-9-ORAMED

ir@oramed.com

投资者关系@奥拉梅德.康姆

www.oramed.com

SOURCE Oramed Pharmaceuticals Inc.

来源：Oramed Pharmaceuticals Inc.